Dr. Black Discusses Immunotherapy Biomarkers in Bladder Cancer

Peter Black, MD
Published: Monday, Aug 07, 2017



Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses immunotherapy biomarkers in bladder cancer.

Investigators are actively investigating biomarkers in bladder cancer. Black says that only about 20% to 25% of patients achieve an objective response to immunotherapy. Moreover, the drugs are expensive and potentially toxic, so it is important to select the right types of patients for them.

The easiest biomarker is PD-L1 immunohistochemistry, but currently has no utility in patients with bladder cancer, Black says.
 


Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses immunotherapy biomarkers in bladder cancer.

Investigators are actively investigating biomarkers in bladder cancer. Black says that only about 20% to 25% of patients achieve an objective response to immunotherapy. Moreover, the drugs are expensive and potentially toxic, so it is important to select the right types of patients for them.

The easiest biomarker is PD-L1 immunohistochemistry, but currently has no utility in patients with bladder cancer, Black says.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x